Dr. Katrin Sternberg, previously a member of the Aesculap Management Board with responsibility for Research & Development, Quality Management, Regulatory Affairs and Medical Scientific Affairs, has decided in agreement with the Supervisory Board to resign from her post due to differences of opinion on the future strategic direction of the division. The company would like to thank her for her many years of valuable contribution to the successful development of Aesculap.
In the future, Prof. Dr. Holger Reinecke will be responsible on the Aesculap Management Board for the Research & Development and Regulatory Affairs divisions and for the SCHÖLLY Group. He will continue to hold the position of CEO of SCHÖLLY, which Prof. Dr. Reinecke has held since 2014. Andreas Hahn will be responsible for the Finance & Controlling, Quality Management, Central Technical Services and Mergers & Acquisitions (M&A) divisions on the Aesculap Management Board.
“With Dr. von Lackum, Professor Reinecke, and Mr. Hahn, Aesculap AG is very well positioned for the future. I am delighted that with Professor Reinecke we have appointed a new Chief Development Officer who is well known to us through his many years of highly successful work at SCHÖLLY and who has already demonstrated his innovation and implementation skills. Mr. Hahn is an Aesculap veteran and his expertise and entrepreneurial skills are highly valued throughout the B. Braun Group,” said Prof. Dr. Heinz-Walter Große, Chairman of the Supervisory Board of Aesculap AG.
Dr. Jens von Lackum says: “I am extremely pleased about the appointment of Professor Holger Reinecke and Andreas Hahn to the Management Board of Aesculap AG. I have worked successfully and trustfully with both for many years. At the same time, with Dr. Ines Lützen as the new Head of Human Resources at Aesculap and Dr. Lubomir Klepac as the new Head of Global Marketing & Sales, we are strengthening the divisional management of Aesculap and considering the diverse orientation of the management team that we are striving for.”
Commenting on Prof. Dr. Reinicke's appointment to the Aesculap Management Board, Regula Schölly, who manages SCHÖLLY together with him and Markus Wintz, adds: “Holger Reinecke has decisively shaped and innovatively developed SCHÖLLY over the past eight years at the helm of the company. I am therefore pleased that he will in future be working in a decisive role at our co-shareholder Aesculap while retaining his role as CEO of SCHÖLLY. In this way, the strategic partnership between Aesculap and SCHÖLLY can be strengthened and, at the same time, the necessary independence and agility of SCHÖLLY for the important OEM business ensured.”
Prof. Dr. Reinecke studied chemistry at the Technical University of Clausthal-Zellerfeld, where he obtained his doctorate in 1990. He then worked for more than 14 years at STEAG microParts GmbH, now Böhringer Ingelheim microParts GmbH. He held various positions in the areas of research & development, production, and market development, most recently being responsible for the medical and measurement technology business unit. From 2004 onwards, Prof. Dr. Holger Reinecke held the Chair of Process Technology at the Institute of Microsystems Technology (IMTEK), Albert Ludwig University Freiburg, for ten years and was also head of the Institute for Micro and Information Technology of the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V. (HSG-IMIT) in Villingen-Schwenningen.
Andreas Hahn began his career at ALNO-Möbelwerke GmbH & Co. KG in Pfullendorf, where he completed an apprenticeship as an industrial clerk. After studying business administration, he moved to Aesculap AG, for which he has now worked for over 30 years. Since 2006, Andreas Hahn has served as Senior Vice President Finance & Controlling in the divisional management of Aesculap.
For more information about the company, visit link below
B. Braun
